We studied 22 new patients ( Table 1) referred for evaluation to the Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS/NIH; ...
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, ...
The bilateral MTLE study (NCT06422923) is a multicenter, open-label trial that will enroll ten adult subjects who will receive a one-time image-guided intracerebral administration of NRTX-1001 into ...
LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Positive decision from data safety monitoring board (DSMB) on review of first cohort safety data greenlights dosing of five additional subjects in the second, highest dose, cohort First two subjects ...
SAN FRANCISCO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today ...
LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback